Scholarlink

Purpose <p>Current therapies for hair loss, including orally administered finasteride, baricitinib, and topically applied minoxidil, are effective but have limitations related to poor patient compliance or low absorption, leading to inconsistent outcomes. This study developed injectable microdepots containing poly(lactic-co-glycolic acid) and rapamycin (RAP<sub>MD</sub>) to address these issues.</p> Methods <p>RAP<sub>MD</sub> was fabricated using an emulsification solvent-evaporation method. The microdepots were comprehensively characterized, including their size, loading capacity, loading efficiency, and release profile. The in vitro and in vivo efficacy of RAP<sub>MD</sub> were evaluated through gene analysis and further assays.</p> Results <p>RAP<sub>MD</sub> exhibited a spherical shape with an average size of 6&#xa0;μm and a loading efficiency of approximately 71%. The in vitro release study revealed a sustained release of rapamycin, with about 70% released over 35 days, remarkably promoting hair regrowth. Importantly, in vivo results demonstrated that low-dose RAP<sub>MD</sub> effectively induced the transition of hair follicles into the anagen phase in mice models via modulating autophagy and Wnt/β-catenin pathway.</p> Conclusion <p>These findings highlight that local injection of PLGA microdepots, with their sustained drug release profile is an effective strategy for promoting hair regrowth in patients experiencing hair loss.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Low-dose rapamycin microdepots promote hair regrowth via autophagy modulation

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年4月9日

查看全文
  • Tiep Tien Nguyen,
  • Trang Nu Huyen Le,
  • Nhu-Nam Nguyen,
  • Simmyung Yook,
  • Dongryeol Ryu,
  • Gorka Orive,
  • Youngdae Gwon,
  • Jong-Hyuk Sung,
  • Jee-Heon Jeong

摘要

Purpose

Current therapies for hair loss, including orally administered finasteride, baricitinib, and topically applied minoxidil, are effective but have limitations related to poor patient compliance or low absorption, leading to inconsistent outcomes. This study developed injectable microdepots containing poly(lactic-co-glycolic acid) and rapamycin (RAPMD) to address these issues.

Methods

RAPMD was fabricated using an emulsification solvent-evaporation method. The microdepots were comprehensively characterized, including their size, loading capacity, loading efficiency, and release profile. The in vitro and in vivo efficacy of RAPMD were evaluated through gene analysis and further assays.

Results

RAPMD exhibited a spherical shape with an average size of 6 μm and a loading efficiency of approximately 71%. The in vitro release study revealed a sustained release of rapamycin, with about 70% released over 35 days, remarkably promoting hair regrowth. Importantly, in vivo results demonstrated that low-dose RAPMD effectively induced the transition of hair follicles into the anagen phase in mice models via modulating autophagy and Wnt/β-catenin pathway.

Conclusion

These findings highlight that local injection of PLGA microdepots, with their sustained drug release profile is an effective strategy for promoting hair regrowth in patients experiencing hair loss.